After an undoubtedly challenging year for the biopharma sector in which macroeconomic risk weighed on investor sentiment, we began to see signs of stability to close out 2022 – prompting increased optimism for a recovery in 2023. William Blair's Biopharma team shares perspectives in The Quarterly Rx: 2022 Year in Review U.S. Biopharma Recap.
William Blair’s 2023 Predictions
- Volatility is here to stay, but “hard landing” is unlikely
- Biopharma sector will outperform the broader market
- Steady cadence of private financings, but “crossover” activity will remain muted
- IPOs will return, but insider support will remain critical
- Follow-on activity will continue to increase
- M&A activity in-line with 2022, but overall partnering to increase
Complete the form below to download your copy of the report.